Company Category: Research

Anivance AI stands at the forefront of intelligent healthcare innovation, specializing in human organ model solutions. A decade of experience with respiratory models has driven us to achieve significant advancements in preclinical testing and earned us the prestigious 2023 Moderna Taiwan mRNA Innovation Award. This recognition is a testament to our unwavering commitment to improving healthcare and reflects our mission: Saving Lives: Now a Reality. Our comprehensive services, designed to accelerate the drug discovery and safety assessment processes, leverage human-simulated data to bridge the gap between laboratory findings and clinical applications. By precisely simulating human responses, we provide the pharmaceutical industry with powerful tools for thorough safety and efficacy evaluation. | Anivance AI is bridging Taiwan’s world-class semiconductor and manufacturing expertise with AI and life sciences, creating a new era of intelligent drug discovery. By integrating AI-powered organ-on-chip technology with automated high-throughput research, we provide pharmaceutical companies with a scalable, self-optimizing platform that accelerates preclinical testing and delivers breakthrough insights. Unlike traditional preclinical models, our platform is continuously learning and adapting, optimizing experiment design, mechanistic analysis (MOA), and real-time data interpretation. By embedding AI agents into automated research workflows, we help pharmaceutical companies make faster, smarter, and more data-driven decisions, significantly reducing preclinical failure rates and improving R&D efficiency. With 25 granted and pending patents, Anivance AI collaborates with leading global pharmaceutical companies and six clinical institutions, ensuring that our technology is aligned with real-world drug development needs. We have validated our high-throughput organ-on-chip platform in lung, liver, and oncology models, with expanding applications in autoimmune diseases and cardiovascular research. Our breakthroughs in inhalable nanoparticle delivery and respiratory disease modeling have earned global recognition, including a nomination for the LUSH Prize in Science. By leveraging Taiwan’s semiconductor supply chain and precision manufacturing ecosystem, we deliver a new level of automation, AI-driven analytics, and experimental scalability that was previously unattainable in biotech. Backed by two of Taiwan’s largest publicly traded companies and validated by over 50 collaborating physicians, Anivance AI is one of Taiwan’s fastest-growing biotech startups, now expanding into the global market. We are not just developing technology—we are reshaping the future of AI-powered drug discovery. With a foundation built on semiconductor precision, AI intelligence, and biotech innovation, Anivance AI provides pharmaceutical companies with the tools to make transformative breakthroughs, faster than ever before. | Anivance AI is a deep tech company developing Physical AI infrastructure for decision-grade human biology in early drug development and translational research. Rather than operating as a service provider or a single model technology, Anivance AI is designed as an integrated system. Physical organ models function as the sensing layer. Standardized execution and biological baselines form the control layer. Structured data intelligence provides the reasoning layer. Together, these components support closed loop experimentation and decision making. We integrate three tightly coupled layers into a single Physical AI platform. 1. Engineering grade physical organ systems Hard structured organ on chip and microphysiological systems designed for long term stability and reproducible operation under dynamic physiological conditions. The systems support continuous microfluidic circulation, vascular side dosing, dynamic exposure workflows including inhalation relevant conditions, and long duration experiments. 2. Standardized biological baselines and profiles Reusable organ and disease profiles that define execution and interpretation standards, reduce variability across batches and operators, and enable cross study comparability. 3. Human data foundry and decision loop Integrated imaging, functional readouts, and structured experimental metadata form a continuously accumulating human data infrastructure. This supports AI assisted analysis, iterative model refinement, and decision oriented reporting aligned with regulatory expectations. The platform has been deployed across lung and inhalation, liver, kidney, CNS and BBB, oncology, and rare disease applications, supporting more than 25 experimental programs across North America, Japan, South Korea, and Europe. | Anivance AI Corporation is a tech startup integrating miniaturized human organ systems on chips with Multi-Agent AI to accelerate drug discovery. Backed by 35 patents and thousands of data points across multiple organ and disease models, Anivance AI advances 20+ projects and expands across North America, Japan, South Korea, and Europe.